Dr. Gordon B. Mills on Moving Toward Patient-Specific Treatment in Breast Cancer
​Gordon B. Mills, MD, PhD, says individualized treatment, as opposed to treating patients solely based on their malignancy type, must happen in order to improve patient outcome.
Gordon B. Mills, MD, PhD, chair of Systems Biology, co-director of the Institute of Personalized Medicine, University of Texas MD Anderson Cancer Center, discusses the oncological trend of moving toward individually treating patients with breast cancer. Mills says this individualized treatment, as opposed to treating patients solely based on their malignancy type, must happen in order to improve patient outcome.
Sequencing Sacituzumab and Other Drugs in HR+, HER2- Breast Cancer
May 16th 2024During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
